Enterococcus faecalis resistant to linezolid:: Case series and review of the literature

被引:31
作者
Burleson, BS
Ritchie, DJ
Micek, ST
Dunne, WM
机构
[1] Barnes Jewish Hosp, Dept Pharm, St Louis, MO 63110 USA
[2] Texas Tech Univ, Hlth Sci Ctr, Sch Pharm, Dept Pharm Practice, Amarillo, TX USA
[3] Washington Univ, Sch Med, St Louis Coll Pharm, Div Pharm Practice, St Louis, MO 63110 USA
[4] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA
来源
PHARMACOTHERAPY | 2004年 / 24卷 / 09期
关键词
Enterococcus faecalis; linezolid; linezolid-resistant E. faecalis; enterococcal isolates; G2576U mutation; 23S rRNA alleles;
D O I
10.1592/phco.24.13.1225.38086
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Reports of linezolid resistance among Enterococcus faecalis have been relatively rare. We describe three patients with linezolid-resistant strains of E. faecalis, discovered after the patients had received long courses (> 30 days) of linezolid therapy. All strains contained the G2576U mutation in 23S rRNA. A literature review revealed one other case in the United States and three cases in Europe; all involved patients who had received long courses of therapy. it appears that recent or extended linezolid therapy may be a risk factor for development of resistant E. faecalis. In patients who have recently been treated with linezolid and have an identified new systemic enterococcal isolate, linezolid sensitivity should be verified as soon as possible to guide therapy. This strategy also should be considered for patients with a breakthrough enterococcal isolate during linezolid therapy.
引用
收藏
页码:1225 / 1231
页数:7
相关论文
共 34 条
[1]   In vitro activities of quinupristin-dalfopristin and cefepime, alone and in combination with various antimicrobials, against multidrug-resistant staphylococci and enterococci in an in vitro pharmacodynamic model [J].
Allen, GP ;
Cha, R ;
Rybak, MJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (08) :2606-2612
[2]   Mechanism of action of oritavancin and related glycopeptide antibiotics [J].
Allen, NE ;
Nicas, TI .
FEMS MICROBIOLOGY REVIEWS, 2003, 26 (05) :511-532
[3]  
[Anonymous], 39 INT C ANT AG CHEM
[4]   Linezolid-resistant enterococci: report of the first isolates in the United Kingdom [J].
Auckland, C ;
Teare, L ;
Cooke, F ;
Kaufmann, ME ;
Warner, M ;
Jones, G ;
Bamford, K ;
Ayles, H ;
Johnson, AP .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 50 (05) :743-746
[5]   Linezolid for the treatment of multidrug-resistant, gram-positive infections: Experience from a compassionate-use program [J].
Birmingham, MC ;
Rayner, CR ;
Meagher, AK ;
Flavin, SM ;
Batts, DH ;
Schentag, JJ .
CLINICAL INFECTIOUS DISEASES, 2003, 36 (02) :159-168
[6]   Isolation of linezolid-resistant Enterococcus faecalis [J].
Boo, TW ;
Hone, R ;
Sheehan, G ;
Walsh, M .
JOURNAL OF HOSPITAL INFECTION, 2003, 53 (04) :312-313
[7]   New developments in tetracycline antibiotics: glycylcyclines and tetracycline efflux pump inhibitors [J].
Chopra, I .
DRUG RESISTANCE UPDATES, 2002, 5 (3-4) :119-125
[8]   Clonal dissemination and colony morphotype variation of vancomycin-resistant Enterococcus faecium isolates in metropolitan Detroit, Michigan [J].
Dunne, WM ;
Wang, W .
JOURNAL OF CLINICAL MICROBIOLOGY, 1997, 35 (02) :388-392
[9]   Vancomycin-resistant enterococcal bacteremia: Natural history and attributable mortality [J].
Edmond, MB ;
Ober, JF ;
Dawson, JD ;
Weinbaum, DL ;
Wenzel, RP .
CLINICAL INFECTIOUS DISEASES, 1996, 23 (06) :1234-1239
[10]   VANCOMYCIN-RESISTANT ENTEROCOCCUS-FAECIUM BACTEREMIA - RISK-FACTORS FOR INFECTION [J].
EDMOND, MB ;
OBER, JF ;
WEINBAUM, DL ;
PFALLER, MA ;
HWANG, T ;
SANFORD, MD ;
WENZEL, RP .
CLINICAL INFECTIOUS DISEASES, 1995, 20 (05) :1126-1133